Clinical Trial Detail

NCT ID NCT02296918
Title ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

prolymphocytic leukemia

chronic lymphocytic leukemia

CLL/SLL

Therapies

Acalabrutinib + Obinutuzumab

Age Groups: adult

No variant requirements are available.